loader2
Partner With Us NRI

Venus Remedies Ltd share Price Today

Company details

305.80
329.00
157.95
430.00
6M Return 29.61%
1Y Return 96.53%
Mkt Cap.(Cr) 435.56
Volume 107,324
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 107,324

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Venus Remedies Ltd shares SWOT Analysis

Strengths (5)

  • Company with high TTM EPS Growth
  • Company with Low Debt
  • Book Value per share Improving for last 2 years

Weakness (6)

  • Inefficient use of capital to generate profits - RoCE declining in the last 2 years
  • Inefficient use of shareholder funds - ROE declining in the last 2 years
  • Inefficient use of assets to generate profits - ROA declining in the last 2 years

Opportunity (1)

  • Highest Recovery from 52 Week Low

Threats (0)

Data not found

Resistance and support

R1 334.6
R2 343.4
R3 357.8
Pivot

320.22

S1 311.4
S2 297.0
S3 288.2
EMA SMA
326.5
344.8
341.9
314.3
324.8
355.7
366.3
307.6
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
SOCIETE GENERALE Bulk Purchase 2024-01-24 380.25 66838 NSE
BNP PARIBAS ARBITRAGE Bulk Sell 2024-01-24 380.24 66948 NSE
GRAVITON RESEARCH CAPITAL LLP Bulk Purchase 2023-11-10 322.38 168234 NSE
Name Category Shares
Pawan Chaudhary PROMOTER 12.82%
Manu Chaudhary PROMOTER 11.73%
Sunev Pharma Solutions Limited PROMOTER 17.21%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Venus Remedies Ltd Stocks COMPARISON

Financials( in Cr) Venus Remedies Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Dr Reddys Laboratories Ltd Zydus Lifesciences Ltd
Price 325.85 1,620.55 1,496.95 6,157.90 1,007.35
% Change 6.75 1.02 2.30 1.88 0.77
Mcap Cr 435.56 388,824.23 120,856.26 102,719.31 101,964.37
Revenue TTM Cr 555.51 43,885.68 15,790.60 24,669.70 17,237.40
Net Profit TTM Cr 26.57 8,560.84 2,513.47 4,507.30 1,997.30
PE TTM 14.04 41.13 29.93 19.30 30.34
1 Year Return 96.53 64.78 68.33 37.28 109.04
ROCE 7.62 16.79 14.76 25.99 16.25
ROE 5.90 16.46 10.66 21.21 14.05
INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 460.34 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 30,755.54 35,765.55
LAST 3M 69,913.40 30,558.15
LAST 6M 130,081.93 64,349.19
LAST 12M 189,259.39 209,046.49

Venus Remedies Ltd Information

Stock PE (TTM)
14.04
Promoter Holding
41.76%
Book Value
352.3434
ROCE
7.62%
ROE
5.9%
Description
  • Incorporated in 1989 Venus Remedies Ltd (formerly known Venus Glucose Pvt Ltd), was converted into Public Limited Company in 1994 and then changed into Venus Remedies Limited. The Company was promoted and managed by Chaudhary & Family. The Company is one of the handful player in pharmaceutical sector to launch injectables globally. It has manufacturing facilities in Panchkula and Baddi , and research and development centre under the name of Venus Medicine Research Centre (in India). In priority, the Company was mainly engaged in I/V Fluids & Injectables, Ceftazidime, Amlodipine, Gliclazide, Lisinopril, etc. The production was started in 1991 with Intravenous/Intramuscular injectible forms at Panchkula district at Haryana. In 1994 it introduced Eye/Ear/Nose drops. The company received the certificate as `WHO-GMP` as specified by WHO,Geneva. Venus Remedies set up a Cephalosporin project with an Australian collaboration with US-FDA standards at a cost of Rs.4.5 crores. The company is manufacturing injections for the top companies like Panacea Biotech ltd,Morepan Labortories ltd etc. In 2001 with the help of Product Development Committee(PDC) Venus Remedies had introduced 13 new products in the Animal Health Division namely Megox-3000,Paroxin-3000,Pisa-3000,Mical,Ronid,Dexolyte and Detox. The year 2005-06 saw many new milestone achievements by the Company like commercial operation of its most modern and techno-savvy manufacturing unit at Baddi, formation of a WOS in Germany and acquisition of a running, German-GMP certified pharmaceutical unit at Werne, Germany, launch of its second R&D Product after DCGI Approval etc. There was a rigorous activity for development on all fronts and the Company made huge investments in projects at Panchkula, Baddi and now at Werne, Germany for renovations, new Projects and acquisition as well. The Company was the first to launch Injection Meropenem in Paediatric Dosage of 125 mg in its Domestic Marketing during the year 2006-07. It further launched fourth research product, a fixed dose combination of cephalosporin with aminoglycoside under the `Tobracef` brand in 2008-09. It launched its anti-cancer drug `Docetaxel` in Europe by end 2011, launched ACHNIL, the once-a-day pain management therapy in India in 2011; launched `Cytomib`, a first-time therapy against blood cancer in 2011; launched `Taxedol` in three strengths-20 mg, 80 mg and 120 mg in 2012. In 2013, the Company established pre-clinical proof of concept for its Drug -Protein-Polymer- Conjugate (DPPC); introduced Ready-to-Use a Single Vial Taxedol in India; launched `Trois`, a miracle nano-emulsion for arthritic Pain; launched `Elores` - CSE 1034, a US patent protected product in India, launched its first OTC product "Ezenus". In 2014, the Company launched ELORES, an antibiotic to fight `superbugs`. In 2021-22, it launched first product in the consumer healthcare space, R3SET - a Pain Management solution. Besides this, Venpocare dealing with Wound Healing was also launched during year 2022. To make internal processes smart and streamlined, many solutions including an automated order processing system, retail billing system, new warehouse (VFC) with barcode automation, etc. were launched. For quicker and more effective decision-making, a BI tool like Tableau was also launched in 2022.

Registered Address

S C No 857 Cabin No 10 2nd Flr, N A C Manimajra, Chandigarh, Chandigarh, 160101

Email : investorgrievance:venusremedies.com; complianceoff
Website : http://www.venusremedies.com
Registrar

Link Intime India Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 526953
NSE Code : VENUSREM
Book Closure Date (Month) : Aug
BSE Group : B
ISIN : INE411B01019

FAQ’s on Venus Remedies Ltd Shares

You can buy Venus Remedies Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Venus Remedies Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Mar 28, 2024 03:56 PM the closing price of Venus Remedies Ltd was ₹ 325.85.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Mar 28, 2024 03:56 PM, the market cap of Venus Remedies Ltd stood at ₹ 435.56.

The latest PE ratio of Venus Remedies Ltd as of Mar 28, 2024 03:56 PM is 14.04

The latest PB ratio of Venus Remedies Ltd as of Mar 28, 2024 03:56 PM is 1.15

The 52-week high of Venus Remedies Ltd share price is ₹ 430.00 while the 52-week low is ₹ 157.95

Download Our

Download App
market app